Revolution Medicines
700 Saginaw Drive
Redwood City
California
94063
United States
76 articles with Revolution Medicines
-
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
6/9/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference.
-
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
4/21/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May 9, 2022, after market close.
-
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
3/9/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the company will make seven oral presentations at the upcoming American Association for Cancer Research Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.
-
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
3/1/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference.
-
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
2/28/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
-
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
2/3/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference.
-
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
1/11/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios.
-
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Revolution Medicines, Inc. today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 40th Annual J.P. Morgan Healthcare Conference.
-
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
11/24/2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference.
-
Revolution Medicines Reports Third Quarter 2021 Financial Results and Update on Corporate Progress
11/10/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.
-
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
11/8/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference.
-
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
11/3/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced that it will report financial results for the third quarter 2021 on November 10, 2021 after market close.
-
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets
9/30/2021
Revolution Medicines, Inc. today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference being held on October 7-10, 2021.
-
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development SummitCompany’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs
9/15/2021
Revolution Medicines, Inc. today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021.
-
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Revolution Medicines, Inc. (Nasdaq: RVMD), today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Revolution Medicines Reports Second Quarter 2021 Financial Results and Update on Corporate Progress
8/11/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced its financial results for the second quarter and six months ended June 30, 2021, and provided a corporate update.
-
It's been a week of promising news for cancer research, with two possible treatment modalities reporting positive results.
-
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
6/24/2021
Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company’s First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor
-
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
6/10/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors.
-
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
6/2/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference.